Evidence map›Paper›PMID 35459930›Full record

ArticleJournal of exposure science & environmental epidemiology2023

Optimal-design domain-adaptation for exposure prediction in two-stage epidemiological studies.

Ron Sarafian, Itai Kloog, Jonathan D Rosenblatt

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of exposure science & environmental epidemiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.5field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 6 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Ron SarafianDepartment of Industrial Engineering, Ben Gurion University of the Negev, Be'er Sheva, Israel. ronsarafian@gmail.com.
Itai KloogDepartment of Geography and Environmental Development, Ben Gurion University of the Negev, Be'er Sheva, Israel.
Jonathan D RosenblattDepartment of Industrial Engineering, Ben Gurion University of the Negev, Be'er Sheva, Israel.
Ben-Gurion University of the Negev · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn the first stage of a two-stage study, the researcher uses a statistical model to impute the unobserved exposures. In the second stage, imputed exposures serve as covariates in epidemiological models. Imputation error in the first stage operate as measurement errors in the second stage, and thus bias exposure effect estimates.

objectiveThis study aims to improve the estimation of exposure effects by sharing information between the first and second stages.

methodsAt the heart of our estimator is the observation that not all second-stage observations are equally important to impute. We thus borrow ideas from the optimal-experimental-design theory, to identify individuals of higher importance. We then improve the imputation of these individuals using ideas from the machine-learning literature of domain adaptation.

resultsOur simulations confirm that the exposure effect estimates are more accurate than the current best practice. An empirical demonstration yields smaller estimates of PM effect on hyperglycemia risk, with tighter confidence bands. SIGNIFICANCE: Sharing information between environmental scientist and epidemiologist improves health effect estimates. Our estimator is a principled approach for harnessing this information exchange, and may be applied to any two stage study.

Indexed as

Models, StatisticalResearch DesignBiasEpidemiologic StudiesHumansDomain-adaptationEnvironmental epidemiologyOptimal-designTwo-stage studies

Identifiers

PMID35459930
OpenAlexW3186077072

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.